Safety and Tolerability of Ciclesonide Nasal Spray in Patients with Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
Study identifier:BY9010/M1-416
ClinicalTrials.gov identifier:NCT00261287
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Clinical Trial Designed to Assess the Safety and Tolerability of Ciclesonide (200 mcg Once Daily), Applied as a Nasal Spray for Twelve Weeks, in the Treatment of Perennial Allergic Rhinitis (PAR) in Pediatric Patients 2-5 Years of Age
Medical condition
Hay Fever
Phase
Phase 3
Healthy volunteers
No
Study drug
Ciclesonide
Sex
All
Actual Enrollment
102
Study type
Interventional
Age
2 Years - 5 Years
Date
Study Start Date: 01 Nov 2005
Primary Completion Date: 01 Jun 2006
Study Completion Date: 01 Jun 2006
Study design
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Oct 2016 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca AstraZeneca
AstraZeneca
